Levoleucovorin calcium
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2008
- First approval year
- 2008
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Levoleucovorin calcium
- Molecular weight
- 511.51
- Structure (SMILES)
- Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2]
- fusilev
- Fusilev
- levoleucovorin calcium
- Levoleucovorin calcium
- (-)-5-FORMYL-(6S)-TETRAHYDROFOLATE CALCIUM SALT
- 5 formyl 6s tetrahydrofolate calcium salt
- 5 fu calcium levofolinate
- Calcium (6s)-folinate
- calcium 6s folinate
- calcium levofolinate
- Calcium levofolinate
- Calcium levofolinate (6s,l)
- calcium levofolinate [INN]
- CALCIUM LEVOFOLINATE [MART.]
- Calcium levofolinate [WHO-DD]
- calcium levofolinate 6s l
- calcium levofolinate hydrate
- Calcium levofolinate hydrate
- calcium levofolinate inn
- calcium levofolinate mart
- calcium levofolinate pentahydrate
- Calcium levofolinate pentahydrate
- calcium levofolinate who dd
- calcium n p 6s amino 5 formyl 1 4 5 6 7 8 hexahydro 4 oxo 6 pteridinyl methyl amino benzoyl l glutamate 1 1
- CALCIUM N-(P-((((6S)-AMINO-5-FORMYL-1,4,5,6,7,8-HEXAHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-L-GLUTAMATE (1:1)
- cl 307 782
- CL 307,782
- cl 307782
- CL-307782
And 29 more, listed on the interactive page.
- ATC classification codes
- V03AF04
Sources for recorded values
- CAS registry numbers
- 80433-71-2
- ChEMBL ID
- CHEMBL1908361
- InChIKey
- KVUAALJSMIVURS-QNTKWALQSA-L
- RxNorm IDs (RxCUI)
- 979509
- FDA ingredient codes (UNII)
- 778XL6VBS8
- 101641675
- 135500522
- 137183587
- Applicant
- ACROTECH BIOPHARMA
- Approval date
- 7 Mar 2008
- Application number
- NDA020140
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Parenteral
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Osteosarcoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001951
- Subject identifier
- D015179
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Carcinoma, Pancreatic Ductal
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005184
- Subject identifier
- D021441
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Colonic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0021063
- Subject identifier
- D003110
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000365
- Condition identifier
- EFO_0000637
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001951
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002280
- Condition identifier
- MONDO_0002280
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005008
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009807
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021063
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0024331
- Highest recorded phase
- 2
- Event
- abdominal pain
- Reports
- 377
- Reporting signal score
- 133.128
- Event
- anaphylactic shock
- Reports
- 27
- Reporting signal score
- 34.274
- Event
- bone marrow failure
- Reports
- 149
- Reporting signal score
- 170.205
- Event
- colon cancer
- Reports
- 21
- Reporting signal score
- 39.8806
- Event
- colorectal cancer metastatic
- Reports
- 56
- Reporting signal score
- 178.702
- Event
- decreased appetite
- Reports
- 103
- Reporting signal score
- 99.2547
- Event
- dehydration
- Reports
- 335
- Reporting signal score
- 216.315
- Event
- dermatitis acneiform
- Reports
- 105
- Reporting signal score
- 235.736
- Event
- diarrhoea
- Reports
- 1,089
- Reporting signal score
- 535.04
- Event
- disease progression
- Reports
- 357
- Reporting signal score
- 324.247
- Event
- disseminated intravascular coagulation
- Reports
- 22
- Reporting signal score
- 41.1193
- Event
- febrile neutropenia
- Reports
- 544
- Reporting signal score
- 808.347
- Event
- fixed eruption
- Reports
- 12
- Reporting signal score
- 36.6455
- Event
- gastrointestinal perforation
- Reports
- 16
- Reporting signal score
- 40.0694
- Event
- haematotoxicity
- Reports
- 119
- Reporting signal score
- 214.399
- Event
- hyperammonaemia
- Reports
- 25
- Reporting signal score
- 64.7165
- Event
- hypertension
- Reports
- 74
- Reporting signal score
- 40.6267
- Event
- hypomagnesaemia
- Reports
- 30
- Reporting signal score
- 52.7844
- Event
- injection site pain
- Reports
- 2
- Reporting signal score
- 121.375
- Event
- interstitial lung disease
- Reports
- 170
- Reporting signal score
- 129.586
- Event
- leukopenia
- Reports
- 207
- Reporting signal score
- 157.744
- Event
- mucosal inflammation
- Reports
- 216
- Reporting signal score
- 293.805
- Event
- neuropathy peripheral
- Reports
- 423
- Reporting signal score
- 439.705
- Event
- neurotoxicity
- Reports
- 138
- Reporting signal score
- 182.939
- Event
- neutropenia
- Reports
- 890
- Reporting signal score
- 1,112.59
And 12 more, listed on the interactive page.
- NCT00195572
- NCT00195585
- NCT01524094
- NCT02337946
- NCT02394795
- NCT02394834
- NCT02697058
- NCT05546853
- Dose
- 7.5 mg
- Route
- Intravenous
- How often
- Every 6 hours
- Administer as infusion starting 24 hours after methotrexate infusion
- Continue until methotrexate level is below 5 x 10-8 M
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 7
- Polar surface area
- 219.84
- Calculated partition coefficient (ALogP)
- -0.73
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 10
- Heavy atoms
- 35
- Molecular formula
- C20H21CaN7O7
- Monoisotopic mass
- 511.1128369
- Natural product
- Yes
- 0143-9558
- 14335-340
- 14335-341
- 43598-771
- 43598-773
- 68083-278
- 68083-279
- 70436-209
- 70436-210
- 71288-104
- 71288-105
- 70121-1572
- Recorded assays
- 4
- Active assays
- 0
Related records
Trials (70)
- A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
- A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
- A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
- A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
- A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
- A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
- A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
- A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
- Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
- Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
- Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Approved for (4)
In development for (5)
- Carcinoma Phase 3
- Exocrine pancreatic carcinoma Phase 2
- Gastric cancer Phase 3
- Malignant colon neoplasm Phase 3
- Pancreatic ductal adenocarcinoma Phase 1
Other linked conditions (1)
- Anemia